Author： Okura Takafumi Miyoshi Ken-ichi Irita Jun Enomoto Daijiro Jotoku Masanori Nagao Tomoaki Watanabe Kouki Matsuoka Hiroshi Ashihara Toshiaki Higaki Jitsuo
Publisher： Informa Healthcare
ISSN： 1064-1963
Source： Clinical and Experimental Hypertension, Vol.35, Iss.8, 2013-12, pp. : 563-569
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Left ventricular hypertrophy (LVH) regression is an important issue in hypertensive patients. Patients with LVH who had received the angiotensin receptor blocker (ARB) treatment for 8 weeks and had not reached the target blood pressure level were enrolled in the study. Patients were assigned to either losartan (50 mg)/hydrochlorothiazide (HCTZ, 12.5 mg) group or ARB + CCB group (usual dose of ARB and calcium channel blocker, CCB). After 48 weeks, LV mass index was found to be reduced significantly in the losartan/HCTZ group but not in the ARB + CCB group. These results suggest that combination therapy of an ARB and diuretic has greater potential to cause regression compared with an ARB and CCB.
Related content
By Ishimitsu Toshihiko Ohno Eri Nakano Nobuyuki Furukata Satoshi Akashiba Akira Minami Junichi Numabe Atsushi Matsuoka Hiroaki
Clinical and Experimental Hypertension, Vol. 33, Iss. 6, 2011-10 ,pp. :
Access to resources
Recommend
By Yutaka Miyashita Mifune Mizuo Kubota Eiji Itoh Hiroshi Saito Ikuo
Clinical and Experimental Hypertension, Vol. 31, Iss. 8, 2009-12 ,pp. :
By Ohta Masanori Tajiri Yuji Yamato Hiroshi Ikeda Masaharu
Clinical and Experimental Hypertension, Vol. 34, Iss. 7, 2012-11 ,pp. :
By Miyagawa Koichi Dohi Yasuaki Nakazawa Ai Sugiura Tomonori Yamashita Sumiyo Sato Koichi Kimura Genjiro
Clinical and Experimental Hypertension, Vol. 32, Iss. 1, 2010-02 ,pp. :